A review of the management of ductal carcinoma in situ following breast conserving surgery.The breast, Dec 2013, Vol. 22(6), p.1019-25.
Boxer, M.M., et al.
http://www.thebreastonline.com/article/S0960-9776(13)00246-4/abstract?rss=yes
Ductal carcinoma in situ (DCIS) is a heterogeneous, pre-malignant disease accounting for 10–20% of all new breast tumours. Evidence shows a statistically significant local control benefit for adjuvant radiotherapy (RT) following breast conserving surgery (BCS) for all patients. The baseline recurrence risk of individual patients varies according to clinical-pathological criteria and in selected patients, omission of RT may be considered, following a discussion with the patient.
